Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience
Investment will contribute to achieve clinical proof-of-concept for
Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program
Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes
Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.
Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech).
The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy.
Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms.
Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member.
Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: ' We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. '
Rachel Mears, Parner at Jeito Capital added: ' Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. '
Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: ' We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.'
About Jeito Capital
Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
For more information, please visit www.jeito.life or follow us on LinkedIn or X.
About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.
Contacts:
Jeito Capital
Rafaèle Tordjman, Founder & CEO
Jessica Fadel, EA
Tel: +33 6 33 44 25 47
Maior
Stéphanie Elbaz – Tel: +33 6 46 05 08 07
ICR Healthcare
Mary-Jane Elliott / Davide Salvi / Kris Lam
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no. 18/351,291 ('291) includes valuable composition-of-matter claims broadly covering therapeutically active ADCs - not limited to individual diseases or therapeutic targets - as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Upon grant, the '291 patent application will provide the Company with potential market exclusivity until 2043 for its proprietary second-generation Accum®-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17). This milestone builds on Defence's established patent portfolio for its foundational Accum® technology, which includes granted patents in the United States (US 11,352,437), Japan (JP 7,126,956), Australia (AU 2017233725), and Israel (IL 261765), with applications currently pending in Canada and Europe. "Second-generation Accum®-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies." This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families. About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information:Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Markel International appoints Sucheng Chang to lead Asia Pacific operations
LONDON, June 9, 2025 /PRNewswire/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced that it has appointed Sucheng Chang as its new Managing Director for Asia Pacific, with effect from 14 July. In his new role, Chang will head up Markel International's Asia Pacific business, which operates from its regional hub in Singapore and from offices in Australia, Hong Kong, China, India, Malaysia and Dubai. He will be responsible for leading the strategic direction of the business, centered on maximizing profitable growth and delivering exceptional client and broker service. Markel International's Asia Pacific business has witnessed significant expansion in recent years, following investment made as part of its Accelerate Asia Pacific strategy. Since 2019, GWP has increased by approximately 600%, underwriting profitability has improved and the number of employees in the region has increased by nearly 300%. Chang will take over from Christian Stobbs, who earlier this year announced his decision to leave the Asia Pacific region, remaining with Markel in another role. Commenting on Chang's appointment, Andrew McMellin, President of Markel International, said: "Sucheng is a highly strategic and well-respected leader within the Asia Pacific market, and I'm thrilled that he's joining Markel to lead our regional business in the next phase of its development. The Accelerate Asia Pacific strategy is a cornerstone of the profitable growth agenda at Markel International. I've no doubt that Sucheng's leadership qualities and his significant experience of scaling insurance operations in Asia will help us to build on this momentum as we push it forward to even greater success." Chang added: "Markel has made huge inroads in Asia Pacific and today is a well-respected insurance partner to clients and trading partners in the region, renowned for its focus on exceptional service and customer outcomes. I therefore couldn't be more excited to lead the next phase of the expansion of Markel's Asia Pacific business, building on the progress that's been made to expand our presence even further and take advantage of the opportunities available in the US$300-billion GWP Asia-Pacific insurance market." Chang arrives at Markel with significant experience scaling insurance operations across the Asia Pacific, most recently as Chief Executive Officer, Hong Kong, for Aon. Prior to joining Aon, Chang spent more than 13 years at Liberty Mutual in strategic roles, including Chief Distribution Officer, Global Retail Markets East and Chief Executive Officer of Liberty Insurance Singapore. He holds an MBA from Yale University and BA from Boston University. About Markel Insurance We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide. View original content to download multimedia: SOURCE Markel
Bloomberg
2 hours ago
- Bloomberg
Insight with Haslinda Amin 6/9/2025
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
